Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 working days
DelveInsight’s, “Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Anti-CD279 (PD-1) Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anti-CD279 (PD-1) Antibody: Overview
PD-1, a protein expressed on T cells, is a member of the CD28 superfamily, and it transmits coinhibitory signals upon engagement with its ligands PD-L1 and PD-L2. Accumulating evidence suggests that the PD-1 system plays pivotal roles in the regulation of autoimmunity, transplantation immunity, infectious immunity, and tumor immunity. Because the interaction of PD-1 with its ligands occurs in the effector phase of killer T cell responses in peripheral blood, anti-PD-1 and anti-PD-L1 monoclonal antibodies are ideal as specific agents to augment T cell responses to tumors with fewer adverse events than with the inhibition of CTLA-4, because the interaction of CTLA-4 with its ligands occurs in the priming phase of T cell responses within lymph nodes. The tolerability of PD-1-pathway blockers and their unique mechanism of action have made them ideal backbones for combination regimen development. Combination approaches involving cytotoxic chemotherapy, anti-angiogenic agents, alternative immune-checkpoint inhibitors, immunostimulatory cytokines and cancer vaccines are currently under clinical investigation.
'Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anti-CD279 (PD-1) Antibody pipeline landscape is provided which includes the disease overview and Anti-CD279 (PD-1) Antibody treatment guidelines. The assessment part of the report embraces, in depth Anti-CD279 (PD-1) Antibody commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anti-CD279 (PD-1) Antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Anti-CD279 (PD-1) Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD279 (PD-1) Antibody Emerging Drugs
Further product details are provided in the report……..
Anti-CD279 (PD-1) Antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD279 (PD-1) Antibody drugs segregated based on following parameters that define the scope of the report, such as:
Anti-CD279 (PD-1) Antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD279 (PD-1) Antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD279 (PD-1) Antibody drugs.
Anti-CD279 (PD-1) Antibody Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Anti-CD279 (PD-1) Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Anti-CD279 (PD-1) Antibody: Overview
PD-1, a protein expressed on T cells, is a member of the CD28 superfamily, and it transmits coinhibitory signals upon engagement with its ligands PD-L1 and PD-L2. Accumulating evidence suggests that the PD-1 system plays pivotal roles in the regulation of autoimmunity, transplantation immunity, infectious immunity, and tumor immunity. Because the interaction of PD-1 with its ligands occurs in the effector phase of killer T cell responses in peripheral blood, anti-PD-1 and anti-PD-L1 monoclonal antibodies are ideal as specific agents to augment T cell responses to tumors with fewer adverse events than with the inhibition of CTLA-4, because the interaction of CTLA-4 with its ligands occurs in the priming phase of T cell responses within lymph nodes. The tolerability of PD-1-pathway blockers and their unique mechanism of action have made them ideal backbones for combination regimen development. Combination approaches involving cytotoxic chemotherapy, anti-angiogenic agents, alternative immune-checkpoint inhibitors, immunostimulatory cytokines and cancer vaccines are currently under clinical investigation.
'Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anti-CD279 (PD-1) Antibody pipeline landscape is provided which includes the disease overview and Anti-CD279 (PD-1) Antibody treatment guidelines. The assessment part of the report embraces, in depth Anti-CD279 (PD-1) Antibody commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anti-CD279 (PD-1) Antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD279 (PD-1) Antibody R&D. The therapies under development are focused on novel approaches to treat/improve Anti-CD279 (PD-1) Antibody.
This segment of the Anti-CD279 (PD-1) Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD279 (PD-1) Antibody Emerging Drugs
- IBI308: Innovent Biologics
- Tislelizumab: BeiGene
Further product details are provided in the report……..
Anti-CD279 (PD-1) Antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD279 (PD-1) Antibody drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Anti-CD279 (PD-1) Antibody
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Anti-CD279 (PD-1) Antibody: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD279 (PD-1) Antibody therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD279 (PD-1) Antibody drugs.
Anti-CD279 (PD-1) Antibody Report Insights
- Anti-CD279 (PD-1) Antibody Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Anti-CD279 (PD-1) Antibody drugs?
- How many Anti-CD279 (PD-1) Antibody drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anti-CD279 (PD-1) Antibody?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD279 (PD-1) Antibody therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anti-CD279 (PD-1) Antibody and their status?
- What are the key designations that have been granted to the emerging drugs?
- GlaxoSmithKline
- Innovent Biologics
- BeiGene
- Shanghai Junshi Biosciences
- Dostarlimab
- Sintilimab
- Tislelizumab
- JS-003
- JS-201
- Toripalimab
Introduction
Executive Summary
Anti-CD279 (PD-1) Antibody: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
IBI308: Innovent Biologics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
JS-201: Shanghai Junshi Biosciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
JS-003: Shanghai Junshi Biosciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Anti-CD279 (PD-1) Antibody Key Companies
Anti-CD279 (PD-1) Antibody Key Products
Anti-CD279 (PD-1) Antibody- Unmet Needs
Anti-CD279 (PD-1) Antibody- Market Drivers and Barriers
Anti-CD279 (PD-1) Antibody- Future Perspectives and Conclusion
Anti-CD279 (PD-1) Antibody Analyst Views
Anti-CD279 (PD-1) Antibody Key Companies
Appendix
Executive Summary
Anti-CD279 (PD-1) Antibody: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
IBI308: Innovent Biologics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
JS-201: Shanghai Junshi Biosciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
JS-003: Shanghai Junshi Biosciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Anti-CD279 (PD-1) Antibody Key Companies
Anti-CD279 (PD-1) Antibody Key Products
Anti-CD279 (PD-1) Antibody- Unmet Needs
Anti-CD279 (PD-1) Antibody- Market Drivers and Barriers
Anti-CD279 (PD-1) Antibody- Future Perspectives and Conclusion
Anti-CD279 (PD-1) Antibody Analyst Views
Anti-CD279 (PD-1) Antibody Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Anti-CD279 (PD-1) Antibody
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Anti-CD279 (PD-1) Antibody
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Anti-CD279 (PD-1) Antibody
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Anti-CD279 (PD-1) Antibody
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
